Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)

After preconditioning with chemotherapy, F01 will be evaluated.

Director Clinical Trial Disclosure Simnova

Yu Hu

Heng Mei

Hongyan Tong

This is a multicenter, open, Phase I clinical study to evaluate the safety and tolerability of F01 in subjects with relapsed/refractory non-Hodgkin lymphoma, and to determine MTD and/or RD.

Approximately 55 participants with relapsed and/or refractory large B-cell lymphoma and follicular lymphoma stage 3b are planned to enroll. This study is divided into two stages: dose escalation and dose extension. In the phase of dose escalation, a single dose escalation study will be carried out first, and then multiple dose escalation studies will be carried out. In the dose expansion phase, up to 3 subjects who had previously received CD19-targeted CAR T cell therapy may enroll.

After the completion of the single dose escalation study, SRC will determine the MTD and/or RD of the single dose escalation phase based on the safety, pharmacokinetic profile (if applicable), immunogenicity, efficacy, and other data available at the time for each dose group. SRC will also determine whether the study will continue with multiple dose escalation studies or a single dose is sufficient to meet therapeutic needs. Multiple dose escalation can be skipped to provide recommendations for dose expansion phase studies based directly on single dose MTD and/or RD doses. After fully evaluating all opinions and data, the sponsor may choose to: 1) Multiple dose escalation studies are not conducted, and the MTD and/or RD doses with a single dose increase are directly entered into the dose expansion phase. In this case, enrolled subjects are continued to receive a single dose during the dose expansion phase to further confirm the safety and efficacy of subjects under RD dose; 2) After the single dose increment, enter the multi-dose increment study, and enter the dose extension phase after confirming the MTD and/or RD doses of multiple doses.

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

A Multicenter, Open Phase I Study to Evaluate the Safety and Pharmacokinetic Profile of F01 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

Explore the correlation among PK , PD（e.g. cytokines）, efficacy, and safety

Explore the correlation among KIR mismatch , efficacy and safety

The incidence, nature and severity of all adverse events, serious adverse events, and abnormal laboratory test results

Optimal objective response rate (ORR), 3-month ORR

Time to reach the maximum concentration (Tmax)

Last detectable concentration point (Clast)

Time of the last detectable concentration (Tlast)

The dynamic changes of cytokine levels in peripheral blood of subjects at baseline and after administration

The number of cases, positive rates, and duration of detection of anti-CAR and IL-15 antibodies (ADA) in subjects' serum at baseline and after administration

Dynamic changes of peripheral blood lymphocyte subsets compared with baseline after administration

Spots Global Cancer Trial Database for after preconditioning with chemotherapy, f01 will be evaluated.